Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay for Cerebral Toxoplasmosis Uses Parasite Antigens

By LabMedica International staff writers
Posted on 10 Nov 2011
Toxoplasma gondii excretory–secretory antigens (ESA) and a crude tachyzoite antigen were used to investigate cerebrospinal fluid (CSF) for active infection.

The parasite antigens were used in an enzyme-linked immunosorbent assay (ELISA) and immunoblotting to determine if anti-ESA antibodies were present in patients infected with human immunodeficiency virus (HIV).

Scientists at the Instituto Adolfo Lutz (Sao Paulo, Brazil) tested CSF from 270 HIV-infected patients were analyzed and divided into three groups according to the presence or absence of active toxoplasmosis. In group I, there were 99 patients with cerebral toxoplasmosis; in group II, there were 112 patients with other opportunistic neurologic diseases and seropositive for toxoplasmosis; and in group III there were 59 patients with other opportunistic neurologic diseases and seronegative for toxoplasmosis.

There was a significantly different mean ELISA-relative values for CSF for group I which was at 7.0 and for group II where it was 3.9, when the crude tachyzoite antigen was used. Samples from groups I and II were reactive by immunoblotting, with similar intensities. In ESA-ELISA, the mean for group I was 9, and group II showed a mean value of 2.7, which was statistically different. Similar results were shown in immunoblotting where a CSF sample from group I reacted well with ESA, and the sample from a group II patient failed to do so. The mean ELISA-relative value of the control group (group III) was 0.5 for the first antigen and 0.4 for the second ESA-ELISA and/or immunoblotting.

The authors concluded that CSF samples could be used for the diagnosis of cerebral toxoplasmosis in association with clinical, serologic, and radiological information, thus providing a simple straightforward methodology, particularly suitable in countries with high prevalence of latent toxoplasmosis in the general population.

The study was published in September 2011, in the journal Diagnostic Microbiology and Infectious Diseases.

Related Links:
Instituto Adolfo Lutz




Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
TORCH Infections Test
TORCH Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.